Mattingly is an associate professor and vice chair of research in the Department of Pharmacotherapy at the University of Utah ...

"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...

The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...

The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...

The Pharmaceutical Care Management Association, which represents PBM's, called the FTC report baseless and "without ...

The accused killer of Brian Thompson cited the industry’s failures as his motive for assassinating the UnitedHealth executive ...

The FTC study examines the practices of PBMs to ensure fair competition and transparency. The FTC found that from 2017 to 2022, the three big PBMs imposed substantial price markups on 51 specialty ...

The Federal Trade Commission on Tuesday released an interim report saying that powerful drug middlemen marked up drugs for ...

Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in ...

The Massachusetts Democrat is working with a Missouri Republican, and House members from each party, to press the FTC to ...

The pharmaceutical supply chain is a sector infamous for glacially slow adjustments, lackluster reform, lack of transparency ...

The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of ...